- Details
- Pedro Barata and Brian Rini unpack the findings and implications of the KEYNOTE-426 trial. The trial assessed the efficacy of a pembrolizumab and axitinib regimen in advanced clear cell kidney cancer, contrasting it with the then-standard sunitinib monotherapy. The KEYNOTE-426 trial's success contributed to changing the standard of care in this field. It demonstrated superior response rates and pr...
|
- Details
- In this discussion, Pedro Barata interviews Dena Battle, who discusses a presentation centered around a survey conducted by Kidney Cancer Research Alliance (KCCure) to understand patient perspectives on kidney cancer treatment. The survey, which received over a thousand responses, specifically targeted metastatic patients and focused on their perceptions of successful treatment, therapy selection,...
|
- Details
- Pedro Barata interviews Nourhan El Ahmar to discuss the significant work conducted by El Ahmar's team. The work focused on a subgroup analysis of the HCRN GU16-260 platform study that investigated the use of nivolumab with ipilimumab as salvage therapy for patients with advanced renal cell carcinoma. El Ahmar delves into the specifics of the trial, explaining how their lab played a crucial role in...
|
- Details
- Pedro Barata converses with Benjamin Berger and Matthew Labriola about their research on the treatment of recurrent metastatic RCC after adjuvant immunotherapy. They delve into the history of trials for adjuvant therapy for RCC, specifically highlighting the major advancements, challenges, and the shift to immunotherapy. The experts discuss adjuvant pembrolizumab's approval, its effectiveness in h...
|
- Details
- Alicia Morgans interviews Toni Choueiri about the CONTACT-03 study, which explored the efficacy of re-challenging patients with renal cell carcinoma (RCC) using a PD-1 or PDL-1 inhibitor, post-tumor progression on prior PD-1 or PDL-1 inhibitor treatments. The study specifically used atezolizumab (a PDL-1 inhibitor) and cabozantinib (a tyrosine kinase inhibitor or TKI). The findings, unfortunately,...
|
- Details
- Alicia Morgans and Toni Choueiri discuss the findings of the COSMIC-313 study, as published in the New England Journal of Medicine. The study examines the efficacy of adding cabozantinib to the Nivolumab-Ipilimumab (NIVO-IPI) regimen for treating advanced renal cell carcinoma. It finds that the triple combination (NIVO-IPI-CABO) significantly improves progression-free survival, especially in inter...
|
- Details
- In this conversation, Pedro Barata interviews Toni Choueiri, discussing the combination of cabozantinib with belzutifan in patients with advanced clear cell renal cell carcinoma (RCC). The study focused on two cohorts: one in the refractory setting and the other in the treatment-naive setting. Dr. Choueiri explains the rationale behind combining a HIF-2 inhibitor with a TKI and why cabozantinib wa...
|
- Details
- Yann Vano joins Pedro Barata to discuss the overall survival and efficacy results from the randomized phase II BIONIKK trial of second-line treatment for patients with metastatic clear cell renal cell carcinoma (mRCC). The trial included patients with ccrc1-4 tumors and randomized them to receive nivo, nivo-ipi, or VEGFR-TKI. In the 18-month follow-up the study showed that nivo-based therapies wer...
|
- Details
- Pedro Barata and Mauricio Burotto discuss the 3-year follow-up of the CheckMate-9ER study. This study compares the combination of nivolumab plus cabozantinib with sunitinib for first-line treatment of advanced renal cell carcinoma (RCC). Nivolumab plus cabozantinib maintained survival and response benefits after 3 years of follow-up. Median overall survival with nivolumab plus cabozantinib improve...
|
- Details
- Laurence Albiges joins Pedro Barata to discuss the CaboPoint study, a clinical trial designed to examine the question of activity and safety of cabozantinib single agent in patients who failed first-line combination therapy for advanced renal cell carcinoma (aRCC). The study has two subgroups - Cohort A and Cohort B. Cohort A is the activity of cabozantinib after nivolumab/pembrolizumab, and Cohor...
|
